Abbvie Inc Stock Probability Of Bankruptcy

ABBV Stock

USD 171.73 3.97 2.37%

AbbVie's chance of distress is under 13% at this time. It has tiny odds of undergoing some form of financial crunch in the near future. AbbVie's Odds of financial turmoil is determined by interpolating and adjusting AbbVie Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the AbbVie balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out AbbVie Piotroski F Score and AbbVie Altman Z Score analysis.

AbbVie Inc Company odds of financial turmoil Analysis

AbbVie's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current AbbVie Probability Of Bankruptcy

Less than 13%

Most of AbbVie's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AbbVie Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of AbbVie probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting AbbVie odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of AbbVie Inc financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.12)

Dividend Share

6.2

Earnings Share

2.87

Revenue Per Share

31.397

Quarterly Revenue Growth

0.038

The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

AbbVie Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for AbbVie is extremely important. It helps to project a fair market value of AbbVie Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since AbbVie's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AbbVie's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AbbVie's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Term Debt	Common Stock	Net Tangible Assets	Retained Earnings	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Treasury Stock	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Current Deferred Revenue
Total Assets		0.35	0.96	0.81	0.93	0.99	-0.4	0.99	0.66	0.97	0.95	0.94	0.78	-0.56	-0.96	0.09	0.95	0.86	0.45	0.02	-0.13	0.63	0.88	-0.32	-0.2	0.33
Total Stockholder Equity	0.35		0.29	0.26	0.46	0.4	-0.26	0.19	-0.24	0.48	0.47	0.07	0.22	0.26	-0.32	-0.21	0.15	0.04	0.1	-0.28	0.75	0.36	0.54	-0.6	-0.08	0.13
Net Debt	0.96	0.29		0.74	0.84	0.96	-0.28	0.95	0.52	0.98	0.89	0.93	0.79	-0.57	-0.96	0.12	0.9	0.82	0.54	0.13	-0.15	0.64	0.85	-0.41	-0.12	0.2
Accounts Payable	0.81	0.26	0.74		0.85	0.83	-0.43	0.8	0.54	0.76	0.81	0.73	0.65	-0.59	-0.87	-0.24	0.79	0.83	0.43	0.02	-0.11	0.51	0.73	-0.46	-0.69	0.68
Net Receivables	0.93	0.46	0.84	0.85		0.95	-0.39	0.89	0.56	0.9	0.97	0.78	0.7	-0.47	-0.87	-0.07	0.83	0.79	0.28	-0.13	0.05	0.61	0.83	-0.46	-0.29	0.48
Good Will	0.99	0.4	0.96	0.83	0.95		-0.38	0.97	0.57	0.98	0.97	0.89	0.77	-0.53	-0.96	0.05	0.91	0.86	0.47	0.04	-0.09	0.63	0.86	-0.43	-0.22	0.38
Short Term Investments	-0.4	-0.26	-0.28	-0.43	-0.39	-0.38		-0.37	-0.36	-0.35	-0.43	-0.33	-0.42	0.44	0.39	0.18	-0.46	-0.44	-0.02	0.34	0.01	-0.33	-0.45	0.03	0.24	-0.24
Total Liab	0.99	0.19	0.95	0.8	0.89	0.97	-0.37		0.73	0.93	0.92	0.97	0.78	-0.63	-0.95	0.13	0.96	0.89	0.45	0.06	-0.27	0.6	0.83	-0.23	-0.19	0.33
Total Current Assets	0.66	-0.24	0.52	0.54	0.56	0.57	-0.36	0.73		0.47	0.54	0.77	0.45	-0.55	-0.56	0.21	0.77	0.65	0.14	-0.11	-0.51	0.3	0.52	0.41	-0.19	0.3
Intangible Assets	0.97	0.48	0.98	0.76	0.9	0.98	-0.35	0.93	0.47		0.94	0.88	0.78	-0.49	-0.95	0.07	0.88	0.79	0.5	0.05	0.0	0.66	0.89	-0.48	-0.14	0.25
Property Plant Equipment	0.95	0.47	0.89	0.81	0.97	0.97	-0.43	0.92	0.54	0.94		0.82	0.77	-0.44	-0.9	-0.14	0.88	0.8	0.31	-0.12	0.06	0.68	0.88	-0.47	-0.26	0.48
Long Term Debt	0.94	0.07	0.93	0.73	0.78	0.89	-0.33	0.97	0.77	0.88	0.82		0.7	-0.64	-0.91	0.2	0.96	0.83	0.49	0.06	-0.36	0.51	0.81	-0.08	-0.15	0.21
Short Term Debt	0.78	0.22	0.79	0.65	0.7	0.77	-0.42	0.78	0.45	0.78	0.77	0.7		-0.48	-0.79	-0.03	0.75	0.73	0.2	0.07	-0.1	0.91	0.72	-0.42	-0.18	0.25
Common Stock	-0.56	0.26	-0.57	-0.59	-0.47	-0.53	0.44	-0.63	-0.55	-0.49	-0.44	-0.64	-0.48		0.57	-0.18	-0.6	-0.76	-0.51	-0.31	0.43	-0.19	-0.34	0.07	0.19	-0.19
Net Tangible Assets	-0.96	-0.32	-0.96	-0.87	-0.87	-0.96	0.39	-0.95	-0.56	-0.95	-0.9	-0.91	-0.79	0.57		-0.01	-0.92	-0.85	-0.5	-0.09	0.16	-0.64	-0.88	0.42	0.36	-0.35
Retained Earnings	0.09	-0.21	0.12	-0.24	-0.07	0.05	0.18	0.13	0.21	0.07	-0.14	0.2	-0.03	-0.18	-0.01		0.01	0.09	0.22	0.51	-0.5	-0.17	-0.16	0.42	0.62	-0.63
Long Term Debt Total	0.95	0.15	0.9	0.79	0.83	0.91	-0.46	0.96	0.77	0.88	0.88	0.96	0.75	-0.6	-0.92	0.01		0.88	0.42	-0.04	-0.27	0.55	0.85	-0.13	-0.28	0.38
Capital Surpluse	0.86	0.04	0.82	0.83	0.79	0.86	-0.44	0.89	0.65	0.79	0.8	0.83	0.73	-0.76	-0.85	0.09	0.88		0.53	0.21	-0.38	0.43	0.63	-0.24	-0.32	0.45
Deferred Long Term Liab	0.45	0.1	0.54	0.43	0.28	0.47	-0.02	0.45	0.14	0.5	0.31	0.49	0.2	-0.51	-0.5	0.22	0.42	0.53		0.44	-0.21	-0.07	0.28	-0.21	-0.12	0.1
Long Term Investments	0.02	-0.28	0.13	0.02	-0.13	0.04	0.34	0.06	-0.11	0.05	-0.12	0.06	0.07	-0.31	-0.09	0.51	-0.04	0.21	0.44		-0.48	-0.09	-0.29	-0.09	0.05	-0.08
Treasury Stock	-0.13	0.75	-0.15	-0.11	0.05	-0.09	0.01	-0.27	-0.51	0.0	0.06	-0.36	-0.1	0.43	0.16	-0.5	-0.27	-0.38	-0.21	-0.48		0.14	0.2	-0.5	-0.01	0.02
Short Long Term Debt	0.63	0.36	0.64	0.51	0.61	0.63	-0.33	0.6	0.3	0.66	0.68	0.51	0.91	-0.19	-0.64	-0.17	0.55	0.43	-0.07	-0.09	0.14		0.69	-0.48	-0.17	0.23
Net Invested Capital	0.88	0.54	0.85	0.73	0.83	0.86	-0.45	0.83	0.52	0.89	0.88	0.81	0.72	-0.34	-0.88	-0.16	0.85	0.63	0.28	-0.29	0.2	0.69		-0.37	-0.3	0.27
Net Working Capital	-0.32	-0.6	-0.41	-0.46	-0.46	-0.43	0.03	-0.23	0.41	-0.48	-0.47	-0.08	-0.42	0.07	0.42	0.42	-0.13	-0.24	-0.21	-0.09	-0.5	-0.48	-0.37		0.31	-0.32
Capital Stock	-0.2	-0.08	-0.12	-0.69	-0.29	-0.22	0.24	-0.19	-0.19	-0.14	-0.26	-0.15	-0.18	0.19	0.36	0.62	-0.28	-0.32	-0.12	0.05	-0.01	-0.17	-0.3	0.31		-0.8
Current Deferred Revenue	0.33	0.13	0.2	0.68	0.48	0.38	-0.24	0.33	0.3	0.25	0.48	0.21	0.25	-0.19	-0.35	-0.63	0.38	0.45	0.1	-0.08	0.02	0.23	0.27	-0.32	-0.8

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition

Predict AbbVie

Based on the latest financial disclosure, AbbVie Inc has a Probability Of Bankruptcy of 13.0%. This is 69.97% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 67.36% higher than that of the company.

AbbVie Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AbbVie's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AbbVie could also be used in its relative valuation, which is a method of valuing AbbVie by comparing valuation metrics of similar companies.

AbbVie is currently under evaluation in probability of bankruptcy category among its peers.

AbbVie Main Bankruptcy Drivers

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	0.0884	0.0307	0.0788	0.0853	0.0361	0.0343
Asset Turnover	0.55	0.37	0.3	0.38	0.42	0.57
Net Debt	26.8B	77.6B	66.9B	54.1B	46.6B	32.2B
Total Current Liabilities	15.6B	28.7B	35.2B	29.5B	37.8B	39.7B
Non Current Liabilities Total	81.7B	108.8B	95.9B	92.0B	86.5B	55.5B
Total Assets	89.1B	150.6B	146.5B	138.8B	134.7B	81.2B
Total Current Assets	49.5B	24.2B	27.9B	28.5B	33.0B	23.5B
Total Cash From Operating Activities	13.3B	17.6B	22.8B	24.9B	22.8B	12.6B

AbbVie ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AbbVie's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AbbVie's managers, analysts, and investors.

Environmental

Governance

Social

AbbVie Fundamentals

	Return On Equity	0.56
	Return On Asset	0.0772
	Profit Margin	0.09 %
	Operating Margin	0.29 %
	Current Valuation	360.25 B
	Shares Outstanding	1.77 B
	Shares Owned By Insiders	0.09 %
	Shares Owned By Institutions	73.32 %
	Number Of Shares Shorted	18.13 M
	Price To Earning	21.28 X
	Price To Book	49.15 X
	Price To Sales	5.34 X
	Revenue	54.32 B
	Gross Profit	41.53 B
	EBITDA	26.36 B
	Net Income	4.88 B
	Cash And Equivalents	11.88 B
	Cash Per Share	6.72 X
	Total Debt	59.38 B
	Debt To Equity	4.37 %
	Current Ratio	0.93 X
	Book Value Per Share	3.41 X
	Cash Flow From Operations	22.84 B
	Short Ratio	3.61 X
	Earnings Per Share	2.87 X
	Price To Earnings To Growth	0.40 X
	Target Price	204.74
	Number Of Employees	50 K
	Beta	0.61
	Market Capitalization	296.46 B
	Total Asset	134.71 B
	Retained Earnings	(1000 M)
	Working Capital	(4.84 B)
	Current Asset	16.31 B
	Current Liabilities	10.89 B
	Annual Yield	0.04 %
	Five Year Return	4.33 %
	Net Asset	134.71 B
	Last Dividend Paid	6.2

About AbbVie Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AbbVie Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AbbVie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AbbVie Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Abbvie Inc Stock Probability Of Bankruptcy

AbbVie Inc Company odds of financial turmoil Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current AbbVie Probability Of Bankruptcy

AbbVie Probability Of Bankruptcy Driver Correlations

AbbVie Probability Of Bankruptcy Peer Comparison

AbbVie Main Bankruptcy Drivers

AbbVie ESG Sustainability

AbbVie Fundamentals

About AbbVie Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for AbbVie Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY